2025-10-19 - Analysis Report
Okay, here's an analysis of UnitedHealth Group (UNH) based on the information you provided.  The report is structured with key data points first, followed by analysis and commentary.

**Report: UnitedHealth Group (UNH) Analysis**

**Company Overview:** UnitedHealth Group Inc. is a diversified health care company providing a wide range of products and services, such as health maintenance organizations, point of service plans, preferred provider organizations, and managed fee-for-service programs.

**1. Performance vs. S&P 500 (VOO)**

*   **UNH Cumulative Return:** -17.06%
*   **VOO Cumulative Return:** 97.05%
*   **Relative Performance Gap:** -112.4
*   **Relative Performance Percentile:** 11.0

**Analysis:** UNH has significantly underperformed the S&P 500. The large negative gap (-112.4) indicates substantial underperformance. The relative performance percentile of 11.0 suggests that UNH's underperformance is near the bottom end of its historical range relative to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
| :----------- | :------ | :------ | :------ | :---- | :------ |
| 2015-2017  | 58.0%   | 66.4%   | 30.0%   | 0.1   | 199.7  |
| 2016-2018  | 41.0%   | 70.4%   | 26.0%   | 0.1   | 225.6  |
| 2017-2019  | 36.0%   | 73.8%   | 14.0%   | 0.2   | 266.2  |
| 2018-2020  | -43.0%  | 81.2%   | -67.0%  | 0.5   | 317.6  |
| 2019-2021  | 16.0%   | 81.2%   | -30.0%  | 1.5   | 454.8  |
| 2020-2022  | -1.0%   | 81.2%   | 0.0%    | 1.5   | 480.2  |
| 2021-2023  | 24.0%   | 80.8%   | 23.0%   | 0.4   | 476.8  |
| 2022-2024  | -27.0%  | 78.8%   | -47.0%  | 0.3   | 458.1  |
| 2023-2025  | -60.0%  | 78.9%   | -121.0% | 1.2   | 323.0  |

**Analysis:**

*   **CAGR:**  CAGR (Compound Annual Growth Rate) is highly variable, with strong positive growth in earlier periods followed by significant negative growth in more recent periods.
*   **MDD:**  MDD (Maximum Drawdown) is consistently high, indicating significant potential for losses from peak to trough.
*   **Alpha:**  Alpha, representing excess return relative to a benchmark, is generally positive in earlier periods but turns sharply negative in more recent years. This reinforces the underperformance relative to the market.
*   **Beta:**  Beta, representing volatility relative to the market, has fluctuated. A Beta of 1.5 in 2019-2022 indicates higher volatility than the market, while recent values around 0.3 suggest lower volatility.
*   **Cap(B):** Market capitalization increased from 2015 to 2021, then dramatically dropped, showing that investors are wary of investing.

**2. Recent Stock Price Action**

*   **Current Price:** 356.60
*   **Previous Close:** 356.67
*   **Change:** -0.02
*   **5-day Moving Average:** 358.60
*   **20-day Moving Average:** 354.11
*   **60-day Moving Average:** 316.00

**Analysis:** The current price is slightly below the 5-day moving average and above the 20-day and 60-day moving averages.  This suggests a potential short-term downward trend, but the price is still supported by longer-term averages. The negligible change from the previous close indicates minimal price movement on the last trading day.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 59.55
*   **PPO:** -0.55
*   **Hybrid Signal:** Cash 79% (Sell 79.7% of holdings)
*   **Recent Relative Divergence Change (20-day):** +0.8 (Short-term Increase)
*   **Expected Return:** -116.7%

**Analysis:**

*   **MRI:** A value of 0.5 suggests a "Low Investment" recommendation, indicating moderate risk.
*   **RSI:** An RSI of 59.55 is neutral, neither overbought nor oversold.
*   **PPO:** A PPO of -0.55 indicates that the short-term moving average is below the long-term moving average, suggesting a potential downtrend.
*   **Hybrid Signal:** The signal recommends a significant reduction in holdings (Sell 79.7%) and a high cash position (79%), reflecting a cautious outlook.
*   **Relative Divergence Change:** The recent increase (+0.8) suggests a potential short-term upward movement, but this is contradicted by other indicators.
*   **Expected Return:** A very negative expected return of -116.7% suggests significant potential underperformance relative to the S&P 500 over the long term.

**4. Recent News & Significant Events**

*   **Goldman Sachs Initiates Coverage with a Buy Rating:**  Potentially positive, but consider the context of overall performance.
*   **CEO Role Split Proposal:**  Could introduce uncertainty and impact stock value.
*   **Medicare Part D Overspending:**  Relevant to UNH's business, potentially a source of both opportunity and risk.
*   **CVS/Rite Aid Acquisition:**  Increased competition in the healthcare space.
*   **Jefferies Adjusts Price Target Upwards:** Positive signal.
*   **UNH Registers Bigger Fall Than the Market:** Confirms recent underperformance.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.93 (~Buy)
*   **Number of Opinions:** 25
*   **Target Price (avg/high/low):** 372.04 / 626.00 / 198.00

**Analysis:**  The analyst consensus is generally positive, with a "Buy" rating and a mean rating indicating a similar sentiment.  The average target price is slightly above the current price, suggesting potential upside. However, the wide range between high and low target prices indicates significant disagreement among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
| :--------- | :---- | :---------- |
| 2025-08-11 | 3.76  | 111.62 B$   |
| 2025-05-07 | 6.9   | 109.58 B$   |
| 2024-11-04 | 6.56  | 100.82 B$   |
| 2024-08-09 | 4.58  | 98.86 B$    |
| 2025-08-11 | 4.58  | 98.86 B$    |

**Analysis:**

*   Revenue has generally been increasing over the past few quarters, indicating top-line growth.  However, the most recent revenue is similar to the previous quarter.
*   EPS (Earnings Per Share) is volatile, with fluctuations from quarter to quarter. The most recent EPS is lower than the previous quarter.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| :----------- | :---------- | :------------ |
| 2025-06-30   | $111.62B    | 17.93%        |
| 2025-03-31   | $109.58B    | 21.70%        |
| 2024-12-31   | $100.81B    | 21.14%        |
| 2024-09-30   | $100.82B    | 22.84%        |
| 2024-06-30   | $98.86B     | 22.31%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE    |
| :----------- | :---------- | :----- |
| 2025-06-30   | $94.72B     | 3.60%  |
| 2025-03-31   | $95.04B     | 6.62%  |
| 2024-12-31   | $92.66B     | 5.98%  |
| 2024-09-30   | $94.53B     | 6.41%  |
| 2024-06-30   | $89.36B     | 4.72%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue shows an increasing trend, but the profit margin has declined in the most recent quarter.
*   **Capital and Profitability:** Equity has fluctuated, and ROE (Return on Equity) has decreased significantly in the most recent quarter.  This suggests declining profitability relative to shareholder equity.

**7. 종합 Analysis**

**Summary:**

UnitedHealth Group (UNH) is currently facing significant headwinds, as indicated by its substantial underperformance relative to the S&P 500, negative expected returns, and cautious market risk indicators. While analyst consensus remains positive, recent financial data reveals declining profit margins and ROE, which are causes for concern. Recent news items present a mixed picture, with some positive developments (Goldman Sachs initiation, Jefferies price target increase) offset by potential challenges (CEO role split, increased competition).

**Key Concerns:**

*   **Underperformance:**  The most glaring issue is UNH's significant underperformance relative to the S&P 500.
*   **Declining Profitability:**  The decrease in profit margins and ROE raises questions about the company's ability to maintain profitability.
*   **High Risk:**  Despite analyst ratings and some positive news, the technical indicators and hybrid signal point to a high-risk investment at the current time.

**Potential Opportunities:**

*   **Analyst Optimism:**  The generally positive analyst ratings suggest that some believe the company can turn things around.
*   **Medicare Part D:**  The issues surrounding Medicare Part D overspending could present opportunities for UNH to innovate and capture market share.

**Recommendation:**

Based on the information provided, a **cautious approach** to UNH is warranted. While analysts are generally positive, the negative performance metrics, declining profitability, and cautious technical indicators suggest that it may be prudent to avoid or reduce exposure to the stock until there are clearer signs of a turnaround. Further investigation is needed to determine the underlying causes of the underperformance and the potential for recovery. The recommendation to hold a high cash position (79%) reinforces this cautious outlook.
